#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adenocarcinoma gastric Granulomatosis with polyangiitis Hypoxic-ischaemic encephalopathy Colon cancer Aicardi-Goutieres syndrome Friedreich's ataxia Arteriosclerosis VEXAS syndrome B-cell small lymphocytic lymphoma recurrent Primary hyperoxaluria Glomerulonephritis membranous Sickle cell anaemia Growth hormone deficiency Carcinoid tumour Immunoglobulin G4 related disease More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis – Trials in Disease Ornithine transcarbamoylase deficiency – Basic Information Skin angiosarcoma – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Myelodysplastic syndrome – Treatment Myelodysplastic syndrome with excess blasts – Basic Information Breast angiosarcoma metastatic – Diagnostics Leiomyosarcoma Cystic fibrosis – Treatment Biotinidase deficiency – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Volixibat Anakinra Efavirenz Siremadlin ALG-000184 Bi 1819479 Mepacrine Cobolimab Ro7589655 Lsta1 Mps-112 Ceritinib Cebsulfase Alfa Saruparib AZD0022 ENSIFENTRINE Op-1250 GSK4418959A Regorafenib TIL CELLS More therapies…

    Learn about Your Condition

    Nodular melanoma Inflammation Hyperparathyroidism primary Myocardial ischaemia Neurodegenerative disorder Uveitis Tardive dyskinesia Endometrial cancer stage I Juvenile psoriatic arthritis Immunosuppression Femoral hernia Hydrocephalus Vulvovaginal pain Juvenile spondyloarthritis Rhabdomyosarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • A study to evaluate the safety and effectiveness of BO-112 injections in patients with resectable primary basal cell carcinoma.

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Basal cell carcinoma
    Investigated Drugs:
    • Polyinosinic:polycytidylic Acid
    Spain

  • Study of orforglipron in people with high blood pressure who are overweight or have obesity

    Not recruiting

    3 1
    Czechia Germany Greece Poland Spain

  • Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Gsk6097608
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    Belgium Finland France Germany Greece Hungary +5

  • Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    Investigated Drugs:
    • VANDETANIB
    • Cabozantinib
    • Selpercatinib
    Belgium Czechia France Germany Greece Italy +3

  • A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

    Not recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Czechia Denmark France Germany +8

  • Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Rocatinlimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16
Previous Page
1 … 911 912 913 914 915 … 1,675
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!